Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.80 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.80 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.80 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.80 |
| ▸ | MAPT | P10636 | 1/20 | 0.80 |
| ▸ | MAOA | P21397 | 1/20 | 0.80 |
| ▸ | SCN1A | P35498 | 1/20 | 0.80 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.80 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.80 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Theracys SCHEMBL18648964 | 1.00 | KCNH2 (0.80) | KCNH2SLC6A2SLC6A4SLC6A3MAPT | |
| Theracys SCHEMBL367470 | 1.00 | KCNH2 (0.80) | KCNH2SLC6A2SLC6A4SLC6A3MAPT | |
| Theracys SCHEMBL116803 | 1.00 | KCNH2 (0.80) | KCNH2SLC6A2SLC6A4SLC6A3MAPT | |
| Theracys SCHEMBL13196454 | 1.00 | KCNH2 (0.80) | KCNH2SLC6A2SLC6A4SLC6A3MAPT | |
| Theracys SCHEMBL16922152 | 1.00 | KCNH2 (0.80) | KCNH2SLC6A2SLC6A4SLC6A3MAPT | |
| Theracys SCHEMBL328885 | 1.00 | KCNH2 (0.80) | KCNH2SLC6A2SLC6A4SLC6A3MAPT | |
| Theracys SCHEMBL11415956 | 0.99 | KCNH2 (0.78) | KCNH2SLC6A2SLC6A4SLC6A3MAPT | |
| Theracys SCHEMBL6716416 | 0.99 | SLC6A2 (0.80) | KCNH2SLC6A2SLC6A4SLC6A3MAPT | |
| Theracys SCHEMBL8958743 | 0.94 | KCNH2 (0.72) | KCNH2SLC6A2SLC6A4SLC6A3MAPT | |
| Cocaine SCHEMBL8050369 | 0.93 | KCNH2 (0.93) | KCNH2SLC6A2SLC6A4SLC6A3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118225543-A | Method suitable for rapid enrichment of 34 kinds of psychotropic drugs in large-volume sewage | 宁波市疾病预防控制中心(宁波市健康教育与促进中心) | 2024-06-21 | — | — | CN | disclosed |
| US-10690651-B2 | Small molecule metabolites for the diagnosis of bacterial vaginosis and assessment of disease risk | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2020-06-23 | — | — | US | disclosed |
| US-20120100171-A1 | HAPTEN-CARRIER CONJUGATES WITH BACTERIAL TOXINS HAVING A SIGNAL PEPTIDE AS CARRIER AND THEIR USE IN IMMUNOGENIC COMPOSITIONS | HENRY WILLIAM (GB) | 2012-04-26 | — | — | US | disclosed |
| EP-2405943-A2 | HAPTEN-CARRIER CONJUGATES WITH BACTERIAL TOXINS HAVING A SIGNAL PEPTIDE AS CARRIER AND THEIR USE IN IMMUNOGENIC COMPOSITIONS | Henry, William (GB) | 2012-01-18 | — | — | EP | disclosed |
| WO-2011000889-A1 | TOPICAL VACCINE FORMULATIONS AND METHODS OF TREATING DRUG ADDICTION USING SAME | HENRY WILLIAM (GB) | 2011-01-06 | — | — | WO | disclosed |
| WO-2010103017-A2 | HAPTEN-CARRIER CONJUGATES WITH BACTERIAL TOXINS HAVING A SIGNAL PEPTIDE AS CARRIER AND THEIR USE IN IMMUNOGENIC COMPOSITIONS | HENRY WILLIAM (GB) | 2010-09-16 | — | — | WO | disclosed |
| US-20100209449-A1 | HAPTEN-CARRIER CONJUGATES FOR USE IN DRUG-ABUSE THERAPY AND METHODS FOR PREPARATION OF SAME | SWAIN PHILIP A | 2010-08-19 | — | — | US | disclosed |
| US-20100105672-A1 | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same | SWAIN PHILIP A | 2010-04-29 | — | — | US | disclosed |
| US-20100068222-A1 | Hapten-carrier conjugates for use in drug abuse therapy and methods for preparation of same | SWAIN PHILIP A | 2010-03-18 | — | — | US | disclosed |
| US-20060286097-A1 | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same | XENOVA RESEARCH LTD. | 2006-12-21 | — | — | US | disclosed |
| US-20060286096-A1 | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same | XENOVA RESEARCH LTD. | 2006-12-21 | — | — | US | disclosed |
| US-20060286094-A1 | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same | XENOVA RESEARCH LTD. | 2006-12-21 | — | — | US | disclosed |
| US-20060286098-A1 | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same | XENOVA RESEARCH LTD. | 2006-12-21 | — | — | US | disclosed |
| US-20060280735-A1 | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same | XENOVA RESEARCH LTD. | 2006-12-14 | — | — | US | disclosed |
| US-20060280736-A1 | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same | XENOVA RESEARCH LTD. | 2006-12-14 | — | — | US | disclosed |
| US-20060239997-A1 | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same | XENOVA RESEARCH LTD. | 2006-10-26 | — | — | US | disclosed |
| US-20060058220-A1 | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same | XENOVA RESEARCH LIMITED | 2006-03-16 | — | — | US | disclosed |
| US-20030069400-A1 | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same | XENOVA RESEARCH LIMITED | 2003-04-10 | — | — | US | disclosed |
| US-20020032316-A1 | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same | CANTAB PHARMACEUTICALS RESEARCH LIMITED | 2002-03-14 | — | — | US | disclosed |
| US-6054127-A | A THERAPEUTIC TREATMENT FOR COCAINE ADDICTION; THE CONJUGATE CAPABLE OF STIMULATING THE PRODUCTION OF ANTI-HAPTEN ANTIBODIES; A THERAPEUTIC IMMUNIZATION REGIMEN ELICITS ANTI-DRUG ANTIBODIES | IMMULOGIC PHARMACEUTICAL CORPORATION (US) | 2000-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120100171-A1 | HAPTEN-CARRIER CONJUGATES WITH BACTERIAL TOXINS HAVING A SIGNAL PEPTIDE AS CARRIER AND THEIR USE IN IMMUNOGENIC COMPOSITIONS | ANTXR2, CD47, TLR5 | KCNH2 3992/4885SLC6A2 2672/4885SLC6A4 3610/4885 |
| US-20100209449-A1 | HAPTEN-CARRIER CONJUGATES FOR USE IN DRUG-ABUSE THERAPY AND METHODS FOR PREPARATION OF SAME | CES2, CD44, CD47 | KCNH2 3653/4885SLC6A2 91/4885SLC6A4 510/4885 |
| US-20100105672-A1 | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same | CES2, CD44, CD47 | KCNH2 3653/4885SLC6A2 91/4885SLC6A4 510/4885 |
| US-20060280736-A1 | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same | CES2, CD44, CD47 | KCNH2 3653/4885SLC6A2 91/4885SLC6A4 510/4885 |
| US-20060239997-A1 | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same | CES2, CD44, CD47 | KCNH2 3653/4885SLC6A2 91/4885SLC6A4 510/4885 |
| US-20100068222-A1 | Hapten-carrier conjugates for use in drug abuse therapy and methods for preparation of same | CES2, CD47, CD44 | KCNH2 3297/4885SLC6A2 107/4885SLC6A4 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.